期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
盐酸氨基葡萄糖片联合玻璃酸钠治疗颞下颌关节骨关节炎的临床随机对照试验 被引量:10
1
作者 李春洁 贾源源 +2 位作者 张绮 史宗道 陈海燕 《华西口腔医学杂志》 CAS CSCD 北大核心 2011年第6期632-635,639,共5页
目的初步探索通过双盲临床随机对照试验评估盐酸氨基葡萄糖治疗颞下颌关节骨关节炎的有效性和安全性。方法 28例被诊断为颞下颌关节骨关节炎的患者被随机分到试验组和对照组。试验组14例接受口服盐酸氨基葡萄糖片(每日服1.44 g)4周;对照... 目的初步探索通过双盲临床随机对照试验评估盐酸氨基葡萄糖治疗颞下颌关节骨关节炎的有效性和安全性。方法 28例被诊断为颞下颌关节骨关节炎的患者被随机分到试验组和对照组。试验组14例接受口服盐酸氨基葡萄糖片(每日服1.44 g)4周;对照组14例口服安慰剂。2组均同时接受颞下颌关节上下腔注射玻璃酸钠治疗(每周1次,共4次)。在试验基线和治疗后第2、3、4周分别测量2组的最大张口度、张口疼痛和张口偏斜;在试验基线和第4周使用OHIP-14量表测量患者的生存质量。统计分析采用意向性分析的方法。结果除对照组2例失访,其余患者均完成治疗及随访。2组基线各指标无明显差异。口服盐酸氨基葡萄糖能显著增加患者的最大张口度(P=0.03)、降低张口疼痛(P=0.02),但在改变张口偏斜和患者生存质量方面其短期效果不明显(P=0.67,P=0.77)。试验过程中未发现严重不良事件。结论盐酸氨基葡萄糖口服与玻璃酸钠关节内注射在颞下颌关节骨关节炎的治疗上有显著的效果和安全性。 展开更多
关键词 盐酸氨基葡萄糖 玻璃酸钠 颞下颌关节骨关节炎 随机对照试验
下载PDF
Qingkailing injection for the treatment of acute stroke: a systematic review and Meta-analysis 被引量:9
2
作者 JiaruiWu Xiaomeng Zhang Bing Zhang 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2014年第2期131-139,共9页
OBJECTIVE: To evaluate systematically the clinical efficacy and safety of Qingkailing (QKL) injection in the treatment of acute stroke. METHODS: Searches for randomized controlled trials into acute stroke treated ... OBJECTIVE: To evaluate systematically the clinical efficacy and safety of Qingkailing (QKL) injection in the treatment of acute stroke. METHODS: Searches for randomized controlled trials into acute stroke treated with QKL injection were performed in the China National Knowledge Infrastructure Database, China Science and Technology Journal Database, Wan fang Database, Chinese Biomedical Literature Database, PubMed and Cochrane Library, from January 1979 to March 2013. Two reviewers independently retrieved the RCTs and extracted the information. The Cochrane risk of bias method was used to assess the quality of the included studies, and a Meta-analysis was conducted with Review Manager 5.2 software. RESULTS: A total of 13 studies with 1110 participants were included. The quality of the studies was generally low. The Meta-analysis indicated that the combined use of QKL and Western Medicine was significantly superior to control group therapy in terms of the total effective rate. The relative risk (RR) in the acute cerebral hemorrhage (ACH) sub-group was 1.17 [95% confidence interval (CI) (1.08, 1.26), P=0.0001]. In the acute cerebral infarction (ACI) sub-group, RR was 1.27 [9.5% CI (1.14, 1.42), P〈0.0001], and in the ACH and ACI mixed sub-group, RR was 1.34 [95% CI (1.20,1.50),P〈0.00001]. Additionally, QKL promoted the absorption of hematoma [mean difference (MD)= - 3.73, 95%0 ( - 4.48, - 2.98), P〈0.000 01], decreased neurological damage in ACI [MD= - 5.60, 95% CI ( - 8.50, - 2.70), P=0.0002] and ACH [MD= 4.08, 95% CI ( - 8.00, 0.16), P=0.04], promoted the recovery of awareness [RR=1.56, 95% CI (1.09, 2.21), P=0.01] and reduced the whole blood viscosity coefficient [MD=- 0.75, 95% CI ( - 1.47, - 0.03), P=0.04]. There were no adverse drug reactions reported in the included studies. CONCLUSION" Based on this systematic review, QKL combined with conventional therapy was effective compared with control treatment. However, because the articles used in the study were not of high quality, further studies should be conducted into the efficacy and safety of QKL in treating acute stroke. 展开更多
关键词 Qingkailing injection STROKE Acutecerebrovascular disease META-ANALYSIS rando-mized controlled trials REVIEW
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部